
Delivering radiation to a tumor through an injected medicine involves a supply chain that begins well before a patient reaches hospital. Nuclear facilities produce the radioactive material, specialist manufacturers turn it into a drug, and delivery teams work to a timetable set partly by radioactive decay.
Two established treatments from Swiss pharma major Novartis (NOVN: VX), Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Lutathera (lutetium Lu 177 dotatate), use lutetium-177 to carry radiation to selected cancer cells. Their growing use has brought the infrastructure behind these medicines into closer view.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze